For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 6,743 | 9,468* | 7,000 | 3,200 |
| General and administrative | 3,808 | 2,756* | 3,040 | 4,016 |
| Total operating expenses | 10,551 | 12,224 | 10,040 | 7,216 |
| Loss from operations | -10,551 | -12,224* | -10,040 | -7,216 |
| Interest income | 523 | 773* | 687 | 754 |
| Other income | - | 0* | - | - |
| Net loss attributable to common stockholders | -10,028 | -11,451* | -9,353 | -6,462 |
| Unrealized (loss) gain on investments | -62 | 2* | 39 | -23 |
| Comprehensive loss | -10,090 | -11,449 | -9,314 | -6,485 |
| Basic EPS | -0.29 | -0.379 | -0.31 | -0.21 |
| Diluted EPS | -0.29 | -0.379 | -0.31 | -0.21 |
| Basic Average Shares | 34,059,876 | 30,198,683 | 30,276,230 | 30,172,328 |
| Diluted Average Shares | 34,059,876 | 30,198,683 | 30,276,230 | 30,172,328 |
AN2 Therapeutics, Inc. (ANTX)
AN2 Therapeutics, Inc. (ANTX)